Lupus Therapeutics Signs a Research Agreement with Takeda for its TAK-079

 Lupus Therapeutics Signs a Research Agreement with Takeda for its TAK-079

Lupus Therapeutics Signs a Research Agreement with Takeda for its TAK-079

Shots:

  • Lupus Therapeutics (subsidiary of Lupus Research Alliance) collaborates with Takeda to evaluate TAK-079 (NCT03724916) in P-I clinical study assessing TAK-079 vs PBO in 24 patients with moderate to severe systemic lupus erythematosus (SLE)
  • The P-I study evaluates Takeda’s TAK-079 safety, efficacy, PK/PD and will conduct in 20 research centers including member of Lupus Therapeutics’ Lupus Clinical Investigators Network (LuCIN)
  • TAK-079 (SC) is a mAb, targets CD38 protein, reduces the immune cell expressing CD38 protein responsible for producing autoantibodies

Click here to read full press release/ article | Ref: Takeda | Image: The Malaysian Reserve

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post